108 related articles for article (PubMed ID: 23793880)
21. JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study.
Rinaldi CR; Rinaldi P; Gemei M; Grimaldi F; Battipaglia G; Del Vecchio L; Martino B; Specchia G; Candoni A; Gugliotta L; Vannucchi AM; Barbui T; Pane F
Am J Hematol; 2010 May; 85(5):383-6. PubMed ID: 20425802
[No Abstract] [Full Text] [Related]
22. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
Tallarico M; Odenike O
Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
[TBL] [Abstract][Full Text] [Related]
23. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K
Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952
[TBL] [Abstract][Full Text] [Related]
24. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
25. Leukemia secondary to myeloproliferative neoplasms.
Dunbar AJ; Rampal RK; Levine R
Blood; 2020 Jul; 136(1):61-70. PubMed ID: 32430500
[TBL] [Abstract][Full Text] [Related]
26. Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies.
Decker M; Lammens T; Ferster A; Erlacher M; Yoshimi A; Niemeyer CM; Ernst MPT; Raaijmakers MHGP; Duployez N; Flaum A; Steinemann D; Schlegelberger B; Illig T; Ripperger T
Leukemia; 2021 Nov; 35(11):3304-3308. PubMed ID: 33692461
[No Abstract] [Full Text] [Related]
27. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
Boultwood J; Perry J; Pellagatti A; Fernandez-Mercado M; Fernandez-Santamaria C; Calasanz MJ; Larrayoz MJ; Garcia-Delgado M; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Hellström-Lindberg E; Cazzola M; Wainscoat JS
Leukemia; 2010 May; 24(5):1062-5. PubMed ID: 20182461
[No Abstract] [Full Text] [Related]
28. BCOR and BCORL1 mutations in pediatric acute myeloid leukemia.
de Rooij JD; van den Heuvel-Eibrink MM; Hermkens MC; Verboon LJ; Arentsen-Peters ST; Fornerod M; Baruchel A; Stary J; Reinhardt D; de Haas V; Pieters R; Zwaan CM
Haematologica; 2015 May; 100(5):e194-5. PubMed ID: 25596268
[No Abstract] [Full Text] [Related]
29. The role of ras gene mutations in myeloproliferative disorders.
Liu ET
Clin Lab Med; 1990 Dec; 10(4):797-807. PubMed ID: 2272174
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
So CC; Ma ES; Wan TS; Yip SF; Chan LC
Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
[No Abstract] [Full Text] [Related]
31. DNMT3A R882H mutation in acute myeloid leukemia cell line SET-2.
Quentmeier H; Pommerenke C; Dirks WG; Fähnrich S; Hauer V; Uphoff CC; Zaborski M; Drexler HG
Leuk Res; 2020 Jan; 88():106270. PubMed ID: 31739141
[No Abstract] [Full Text] [Related]
32. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia.
Tiacci E; Grossmann V; Martelli MP; Kohlmann A; Haferlach T; Falini B
Haematologica; 2012 Jan; 97(1):3-5. PubMed ID: 22210327
[No Abstract] [Full Text] [Related]
33. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
34. ETV6 mutations and loss in AML-M0.
Silva FP; Morolli B; Storlazzi CT; Zagaria A; Impera L; Klein B; Vrieling H; Kluin-Nelemans HC; Giphart-Gassler M
Leukemia; 2008 Aug; 22(8):1639-43. PubMed ID: 18305557
[No Abstract] [Full Text] [Related]
35. Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases.
Voso MT; Fabiani E; Fianchi L; Falconi G; Criscuolo M; Santangelo R; Chiusolo P; Betti S; D'Alo' F; Hohaus S; De Stefano V; Leone G
Leukemia; 2013 Apr; 27(4):982-5. PubMed ID: 22964944
[No Abstract] [Full Text] [Related]
36. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
[No Abstract] [Full Text] [Related]
37. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
38. Chromosome 7q31.1 deletion in myeloid neoplasms.
Tripputi P; Bianchi P; Fermo E; Bignotto M; Zanella A
Hum Pathol; 2014 Feb; 45(2):368-71. PubMed ID: 24439223
[TBL] [Abstract][Full Text] [Related]
39. Deletion of the long arm but not the 5q31 region of chromosome 5 in myeloid malignancies.
Brezinova J; Zemanova Z; Bystricka D; Sarova I; Lizcova L; Malinova E; Izakova S; Sajdova J; Sponerova D; Jonasova A; Cermak J; Michalova K
Leuk Res; 2012 Mar; 36(3):e43-5. PubMed ID: 22153775
[No Abstract] [Full Text] [Related]
40. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
